Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...

Swiss drugmaker Novartis on Friday agreed to buy a breast cancer drug candidate for up to $3 billion from U.S. biotech firm ...

March 17 () - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression ‌or death by 40% in ...

A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

March 20 (Reuters) - The U.S. Food and Drug Administration said on Friday it approved Bristol Myers Squibb's combination ...

Pegvisomant, developed by professor John Kopchick in 1987, shows potential to make treatment-resistant lung cancer cells more ...

Looking to bolster its pipeline, Novartis is buying a breast cancer drug candidate for $2 billion from Delaware-based ...

Novartis AG agreed to buy an experimental breast cancer drug from Synnovation Therapeutics for as much as $3 billion to ...

A protein already targeted by FDA-approved cancer drugs may also help the body fight influenza, according to new research ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT inhibitor Truqap in prostate cancer.

Researchers at the Technical University of Munich (TUM) have increased the effectiveness of a standard antibiotic by a factor ...